FDA approves first m RNA-based flu vaccine
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
26 sources checked · Left, Center, and Right included · 1h ago
CBS News - US and The Epoch Times describe the same event in different terms.

DIFFERENT SPIN
HOW EACH SIDE WORDED IT
As of August 6, 2026 at 3:13 PM, this is how Optics News reads the wording differences in this story.
26 sources across Left, Center, and Right all describe the same event.
67/99 — meaningful wording shift across the spectrum.
WHAT EACH SIDE EMPHASIZED
CBS News - US · Center-left · News report
WDSU New Orleans (Hearst) · Center · News report
The Epoch Times · Right · News report
SEE THE HEADLINES
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The shot, named m Flusiva, is intended for adults age 50 or older.
The shot, named m Flusiva, is intended for adults age 50 or older.
The agency requires more data to prove efficacy for over 65s, but has licensed the first m RNA-based flu shot in the United States for those aged 50–64.
The U.S. Food and Drug Administration has approved a new seasonal flu vaccine from Moderna that uses m RNA technology, the drugmaker announced.
The m Flusiva vaccine for older people is first made with m RNA platform key to ending coronavirus pandemic The Food and Drug Administration has approved a new kind of flu vaccine for older...
Takeda's narcolepsy drug approved, the first m RNA flu shot approved, and more biotech updates from The Readout
The shot, made by Moderna, will be available for this year's upcoming flu season.
The U.S. Food and Drug Administration has approved a new m RNA-based seasonal flu vaccine for people 50 and older, Moderna said this week.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
This flu shot, m Flusiva, was shown in a clinical trial to be up to 27 percent more effective than a standard flu jab
SOURCE MAP CHANGES
Aug 6, 1:00 PM: Scientific American joined the source map.
Aug 6, 1:03 PM: WDSU New Orleans (Hearst) joined the source map.
Aug 6, 1:03 PM: WCVB Boston (Hearst) joined the source map.
Aug 6, 1:03 PM: WMUR9 (Hearst, Manchester NH) joined the source map.
Now: Wording Gap is 67/99 and story health is stable · 26 sources · all three buckets · comparable news format.